Lung cancer and serious bone problems

Lung Cancer and Other Solid Tumors

My Lung Cancer Has Spread to My Bones But
I Still Push Forward

XGEVA® helps protect against serious bone problems1

XGEVA® is a prescription medicine used to prevent serious bone problems in patients with bone metastases from solid tumors.1

Serious bone problems are defined as1:

  • Broken bones (fractures)
  • The need for bone surgery
  • Radiation treatments for bone pain
  • Pressure on the spinal cord (spinal cord compression)

For people with bone metastases from lung cancer and other solid tumors,

XGEVA® helps provide the protection you seek from serious bone problems1

In a study of people with lung cancer and other solid tumors, including multiple myeloma

XGEVA® delayed serious bone problems for

20.5 months

This was 4.2 months longer than another bone-targeting medicine, zoledronic acid, also known as ZA (16.3 months)1*

  1. In a study of 1,776 patients with bone metastases from other solid tumors or multiple myeloma.1

In the same study, but excluding people with multiple myeloma

XGEVA® delayed serious bone problems for

21.4 months

This was 6 months longer than ZA (15.4 months)2†

19% lower chance of serious bone problems with XGEVA than with zoledronic acid

less likely to have serious bone problems with XGEVA® than with ZA2†

  1. In a post hoc subgroup analysis of 1,597 patients with bone metastases from lung cancer and other solid tumors.2

XGEVA® was studied to prevent serious bone problems in patients with bone metastases from over 15 solid tumor cancers.3

This study included patients with the following solid tumors3:

  • Non-small cell lung cancer (12%)
  • Renal cancer (2%)
  • Small cell lung cancer (2%)

XGEVA® was also studied in other types of cancer (each with less than 5% of patients), which included1,4:

  • Biliary tract cancer
  • Bladder cancer
  • Cervical cancer
  • Colon cancer
  • Endometrial cancer
  • Esophageal cancer
  • Gastric cancer
  • Head and neck cancer
  • Hodgkin's lymphoma
  • Melanoma
  • Neuroendocrine/carcinoid cancer
  • Non-Hodgkin's lymphoma
  • Ovarian cancer
  • Pancreatic cancer
  • Rectal cancer
  • Soft tissue sarcoma
  • Testicular cancer
  • Thyroid cancer

Explore XGEVA® in other cancer types

Important Safety Information


Do not take XGEVA® if you have low blood calcium (hypocalcemia). Your low blood calcium must be treated before you receive XGEVA®. XGEVA® can significantly lower the calcium levels in your blood and some deaths have been reported. Take calcium and vitamin D as your doctor tells you to. Tell your doctor right away if you experience spasms, twitches, cramps, or stiffness in your muscles or numbness or tingling in your fingers, toes, or around your mouth.

Do not take XGEVA® if you are allergic to denosumab or any of the ingredients of XGEVA®. Serious allergic reactions have happened in people who take XGEVA®. Call your doctor or go to your nearest emergency room right away if you have any symptoms of a serious allergic reaction, including low blood pressure (hypotension); trouble breathing; throat tightness; swelling of the face, lips, or tongue, rash; itching; or hives.

What is the most important information you should know about XGEVA®?

Do not take XGEVA® if you take Prolia. XGEVA® contains the same medicine as Prolia® (denosumab).

Severe jaw bone problems (osteonecrosis)

Unusual thigh bone fracture

Risk of high calcium levels in patients with Giant Cell Tumor of Bone and in patients who are still growing

Increased risk of broken bones in the spine after discontinuing XGEVA®

Possible harm to your unborn baby

Tell your doctor if you:

While taking XGEVA®, you should:

What are the possible side effects of XGEVA®?

These are not all the possible side effects of XGEVA®. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see Full Prescribing Information.

Indication

XGEVA® is a prescription medicine used to prevent fracture, spinal cord compression, or the need for radiation or surgery to bone in patients with multiple myeloma and in patients with bone metastases from solid tumors.

References:
  1. XGEVA® (denosumab) prescribing information, Amgen.
  2. Henry D, Vadhan-Raj S, Hirsh V, et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2014;22(3):679-687.
  3. Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48(16):3082-3092.
  4. Data on file, Amgen.